medrxiv
preprint
abstract
purpos
coronavirus
may
activ
dysregul
host
immun
respons
exploratori
studi
suggest
level
elev
case
complic
biolog
tocilizumab
may
benefici
undertook
systemat
review
metaanalysi
assess
evid
field
method
systemat
search
medlin
embas
studi
investig
immunolog
respons
treatment
tocilizumab
addit
grey
literatur
search
undertaken
metaanalysi
undertaken
use
random
effect
model
novel
coronaviru
sever
acut
respiratori
syndromecoronaviru
emerg
decemb
wuhan
caus
febril
respiratori
ill
known
coronaviru
diseas
third
zoonot
coronaviru
infect
human
past
two
compar
predecessor
demonstr
rapid
capac
dissemin
alreadi
infect
patient
worldwid
transmiss
fuell
high
intrins
reproduct
number
burgeon
commun
potenti
occult
transmiss
presymptomat
incub
period
china
nearli
onefifth
infect
patient
experi
sever
critic
overal
case
fatal
rate
patient
experienc
sever
complic
prevent
vaccin
effect
antivir
remain
unavail
hostdirect
therapeut
employ
exist
immunomodulatori
agent
must
explor
coronavirus
observ
activ
excess
dysregul
host
immun
biolog
agent
tocilizumab
human
monoclon
antibodi
target
receptor
block
downstream
proinflammatori
effect
approv
food
drug
associ
cr
induc
chimer
antigen
receptort
cell
therapi
immunemedi
rheumat
diseas
exploratori
studi
suggest
inhibit
may
benefici
patient
sever
despit
absenc
definit
evid
high
drug
cost
unclear
potenti
harm
alreadi
incorpor
manag
guidelin
gener
china
itali
may
thu
incit
clinic
use
without
definit
evid
support
safeti
therefor
design
systemat
review
metaanalysi
assess
evid
describ
respons
patient
exist
plan
studi
investig
efficaci
tocilizumab
guid
patient
manag
clarifi
guidelin
develop
inform
futur
trial
field
undertook
systemat
review
metaanalysi
investig
dysregul
patient
diagnos
potenti
role
suppress
administr
tocilizumab
articl
elig
inclus
observ
cohort
casecontrol
random
control
trial
rct
character
either
serum
dynam
therapeut
respons
tocilizumab
adult
pediatr
patient
diagnos
systemat
review
undertaken
methodolog
accord
cochran
report
consist
prefer
report
item
systemat
review
metaanalys
prisma
priori
protocol
design
regist
prospero
identif
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
design
high
sensit
search
strategi
combin
free
text
keyword
search
term
synonym
cluster
combin
cluster
either
tocilizumab
systemat
search
publish
articl
ovid
medlin
embas
prepubl
manuscript
preprint
server
biorxiv
medrxiv
chinxiv
googl
scholar
plan
trial
clinic
trial
registri
clinicaltrialsgov
chines
clinic
trial
registri
search
span
januari
march
exclus
made
languag
diseas
sever
outcom
report
conduct
expand
ovid
medlin
embas
databas
search
januari
march
publish
cohort
studi
report
patient
characterist
outcom
see
appendix
full
search
strategi
ensur
studi
report
level
identifi
refer
list
includ
articl
also
review
potenti
elig
citat
two
review
eac
hh
independ
undertook
twostep
select
studi
screen
via
titl
abstract
follow
fulltext
review
studi
includ
rct
observ
cohort
casecontrol
design
describ
two
patient
diagnos
report
either
measur
cytokin
level
focu
tocilizumab
administr
data
extract
undertaken
duplic
eac
hh
via
standard
data
extract
tabl
data
extract
articl
text
tabl
graph
employ
figur
analysi
tool
quantit
estim
curv
data
data
collect
studi
design
set
patient
demograph
diseas
characterist
level
immun
marker
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
indic
system
inflamm
inflammatori
marker
cytokin
level
immunomodulatori
agent
administ
corticosteroid
intraven
immunoglobulin
ivig
outcom
consist
complic
infect
hospit
intens
care
unit
icu
admiss
ard
invas
mechan
ventil
renal
replac
therapi
sever
diseas
clinic
score
tool
chines
new
coronaviru
pneumonia
prevent
control
program
other
death
conflict
resolv
consensu
discuss
count
data
nomin
variabl
present
proport
percentag
continu
data
present
mean
standard
deviat
sd
median
interquartil
rang
iqr
rang
measur
associ
relat
clinic
characterist
receipt
tocilizumab
downstream
clinic
outcom
present
unadjust
adjust
form
avail
data
permit
result
describ
summar
quantit
semiqualit
data
deem
adequ
homogen
term
patient
characterist
intervent
clinic
outcom
metaanalysi
undertaken
use
random
effect
model
statist
homogen
median
iqr
convert
mean
sd
maxim
number
studi
elig
continu
data
comput
ratio
mean
rom
studi
undertook
metaanalysi
via
gener
invers
varianc
method
dersimonian
laird
produc
pool
measur
associ
correspond
confid
interv
ci
forest
prespecifi
subgroup
analys
conduct
regard
individu
subdefinit
complic
diseas
defin
primari
studi
investig
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
follow
remov
duplic
databas
search
identifi
uniqu
citat
articl
assess
via
full
text
eight
studi
elig
inclus
figur
addit
three
articl
identifi
via
preprint
server
search
five
plan
inprocess
clinic
trial
identifi
via
clinic
trial
registri
search
total
articl
therefor
elig
inclus
eleven
contribut
qualit
synthesi
six
undergo
quantit
synthesi
metaanalysi
figur
individu
studi
characterist
patient
demograph
present
tabl
inflammatori
marker
therapeut
intervent
diseas
complic
present
tabl
summari
regist
clinic
trial
plan
underway
investig
tocilizumab
treatment
present
tabl
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ten
cohort
studi
describ
immunolog
respons
patient
diagnos
mean
age
femal
studi
set
china
one
exclus
recruit
hospit
inpati
studi
report
use
immunomodulatori
therapi
corticosteroid
commonli
administ
agent
receiv
patient
studi
report
surviv
global
mortal
among
patient
diagnos
tabl
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
one
studi
examin
clinic
impact
tocilizumab
sever
nonrandom
openlabel
clinic
trial
patient
sever
critic
treat
tocilizumab
mean
age
year
patient
femal
critic
diseas
identifi
four
patient
patient
receiv
institut
standard
care
includ
lopinavir
methylprednisolon
well
tocilizumab
mg
intraven
one
two
dose
eighteen
patient
receiv
tocilizumab
three
patient
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
tabl
base
china
one
sinc
cancel
princip
investig
one
plan
yet
recruit
two
studi
underway
multicentr
rct
third
rct
pend
recruit
cumul
anticip
sampl
size
four
plan
studi
methodolog
design
complementari
target
patient
popul
allcom
allcom
elev
sever
case
elev
sever
case
elev
meet
diagnost
criteria
grade
cr
compar
support
therapi
favipiravir
continu
renal
replac
therapi
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
cohort
studi
assess
inflammatori
respons
covid
figur
mostli
driven
lack
control
confound
potenti
inconsist
measur
inflammatori
mediat
studi
assess
tocilizumab
treatment
risk
bia
determin
sever
follow
assess
robinsi
systemat
review
metaanalysi
demonstr
serum
level
significantli
elev
set
sever
diseas
metaanalysi
avail
data
indic
increas
level
significantli
associ
advers
clinic
outcom
includ
icu
admiss
ard
death
patient
complic
form
nearli
threefold
higher
serum
level
noncompl
diseas
singl
nonrandom
studi
publish
investig
effect
tocilizumab
treatment
decreas
level
serum
improv
clinic
radiolog
statu
absenc
mortal
observ
increasingli
recogn
dysregul
host
immun
respons
foreign
infecti
pathogen
integr
develop
target
organ
dysfunct
major
contributor
morbid
mortal
specif
system
inflammatori
respons
sepsi
demonstr
overlap
cr
patient
complic
ard
hyperactiv
humor
immun
system
promin
respons
may
suggest
part
pathogenesi
complic
diseas
involv
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
although
design
report
accord
standard
systemat
review
employ
highli
sensit
search
strategi
includ
grey
literatur
studi
import
limit
much
inher
methodolog
qualiti
includ
primari
studi
primari
studi
elig
inclus
conduct
china
sever
studi
recruit
particip
centr
none
includ
studi
describ
data
previous
publish
remain
theoret
encount
high
level
statist
heterogen
metaanalysi
compar
level
patient
complic
noncompl
diseas
although
perform
prespecifi
sensit
analys
fail
suffici
explain
heterogen
residu
heterogen
may
arisen
multipl
sourc
variabl
studi
promin
due
like
differ
patient
characterist
lack
consecut
enrol
variabl
time
measur
absenc
set
definit
support
care
differ
adjuv
immunomodulatori
medic
receiv
corticosteroid
ivig
may
affect
respons
patient
outcom
studi
includ
review
rate
moder
high
risk
bia
reflect
gener
low
methodolog
qualiti
primarili
driven
lack
control
confound
inconsist
unclar
context
measur
perform
potenti
select
bia
due
lack
consecut
patient
enrol
lastli
identifi
singl
nonrandom
singlearm
studi
investig
effect
tocilizumab
treatment
patient
promis
provid
lowlevel
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
evid
efficaci
safeti
drug
treatment
sever
primarili
consid
hypothesisgener
time
systemat
review
metaanalysi
demonstr
serum
level
significantli
elev
set
complic
diseas
increas
level
turn
significantli
associ
advers
clinic
outcom
suggest
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
